INTERVIEW: Lupin head on US plans, fair biosimilar pricing and 'letting go'

For those who've interacted with Lupin's founder chairman Dr Desh Bandu Gupta, his son Nilesh, who took over as managing director of the Indian pharma firm in September, is perhaps quite a contrast. Not that Dr Gupta ever held back, but Mr Gupta junior clearly represents India's young, ambitious and plain-speaking bosses, who are able to discuss both their company's successes and challenges, including some personal ones, with the same relative ease.

For those who've interacted with Lupin's founder chairman Dr Desh Bandu Gupta, his son Nilesh, who took over as managing director of the Indian pharma firm in September, is perhaps quite a contrast. Not that Dr Gupta ever held back, but Mr Gupta junior clearly represents India's young, ambitious and plain-speaking bosses, who are able to discuss both their company's successes and challenges, including some personal ones, with the same relative ease.

In a freewheeling interview with Scrip, Mr Gupta outlined Lupin's planned growth trajectory in the US, where the next batch...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Japan

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

 
• By 

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.

Sumitomo Parkinson’s Filing A Pivotal Moment For Japan’s iPSC Ambitions

 
• By 

Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By 

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By 

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

More from Focus On Asia

China’s BRL Gears Up For First UCAR-T Trial In Leukemia/Lymphoma

 
• By 

Shanghai-based BRL Medicine is building a novel pipeline led by universal CAR-Ts. Its founder talks to Scrip about the benefits of this approach, China's potential advantages in the field and challenges faced by new ventures.

BeBetter, Trinomab Advance IPOs On China’s STAR Market In Firsts Since Policy Easing

 

BeBetter becomes first unprofitable innovative drug maker to have application for an IPO on Shanghai's STAR Market cleared by China’s top securities regulator, while Trinomab becomes first among peers to have IPO filing accepted.

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By 

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis